




RealRate

PHARMACEUTICAL 2021

DMK Pharmaceuticals Corp
Rank 348 of 394



The relative strengths and weaknesses of DMK Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DMK Pharmaceuticals Corp compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 26% points. The greatest weakness of DMK Pharmaceuticals Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 136% points.

The company's Economic Capital Ratio, given in the ranking table, is 119%, being 137% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	12,524
Cost of Goods Sold	14,894
Intangible Assets	7,158
Liabilities, Current	19,926
Liabilities, Non-Current	891
Other Assets	1,599
Other Compr. Net Income	0
Other Expenses	12,553
Other Liabilities	6,553
Other Net Income	-389
Other Revenues	16,527
Property and Equipment	9,587
Research and Development	8,281
Selling, General and Administrative Expense	30,581

Output Variable	Value in 1000 USD
Assets	30,867
Liabilities	27,370
Expenses	66,308
Revenues	16,527
Stockholders Equity	3,498
Net Income	-50,170
Comprehensive Net Income	-50,170
BaseVar	70,731
ECR before Limited Liability	-146%
Economic Capital Ratio	119%